The gallbladder and bile system represent an understudied aspect of PFAS toxicology that may be significant for both the health effects of PFAS exposure and for understanding how PFAS are metabolized and excreted by the body. Research on PFAS and gallbladder health is limited but growing, with findings that connect PFAS to altered bile acid metabolism, gallstone risk, and liver-gallbladder-intestinal axis dysfunction.
The Liver-Bile-Gallbladder System and PFAS
The liver processes blood from the entire digestive tract, making it the primary organ for PFAS metabolism and the site of highest PFAS accumulation. The liver produces bile — a complex fluid containing bile acids, cholesterol, lecithin, and bilirubin — which is stored and concentrated in the gallbladder and released into the small intestine to aid fat digestion.
PFAS interact with this system in multiple ways:
- PFAS bind to hepatic proteins and disrupt lipid metabolism (PFAS are well-established activators of PPAR-alpha, a nuclear receptor controlling fat burning and bile acid synthesis)
- Some PFAS are excreted in bile — this enterohepatic circulation means PFAS can cycle between liver and intestine repeatedly, prolonging their residence in the body
- PFAS effects on cholesterol metabolism affect bile composition, since bile is the primary route by which the body eliminates excess cholesterol as bile acids
PFAS and Gallstone Risk
Gallstones form when bile becomes supersaturated with cholesterol or other components, leading to crystal formation in the gallbladder. Given PFAS effects on cholesterol metabolism and bile acid synthesis, a mechanistic connection to altered bile composition and gallstone risk is plausible.
Epidemiological studies examining PFAS and gallstone disease are limited. Some population-level analyses have found elevated rates of gallbladder disease in communities with high PFAS exposures, but definitive causality has not been established in well-controlled studies. This represents a research gap given the mechanistic plausibility.
Non-Alcoholic Fatty Liver Disease Connection
The strongest documented PFAS-related hepatic condition is non-alcoholic fatty liver disease (NAFLD) — a spectrum of conditions ranging from simple fat accumulation in liver cells to non-alcoholic steatohepatitis (NASH) with inflammation and fibrosis. Multiple studies have found associations between higher serum PFAS levels and elevated liver enzymes (indicating liver stress) and increased NAFLD diagnosis risk.
NAFLD and gallbladder disease are closely related — fatty liver disease promotes cholesterol saturation of bile and gallstone formation, creating a mechanistic linkage between PFAS-driven liver dysfunction and gallbladder consequences.
Bile Acid Metabolism and Cholesterol Clearance
The ability of the body to clear excess cholesterol depends critically on liver conversion of cholesterol to bile acids. PFAS activation of PPAR-alpha is a central regulator of this process. In some PFAS-exposed animal models, altered bile acid synthesis has been documented, potentially impairing cholesterol clearance and contributing to the hypercholesterolemia (high blood cholesterol) consistently associated with PFAS exposure in humans.
This mechanism also explains a potentially therapeutic opportunity: bile acid sequestrant medications (cholestyramine, colestipol) interrupt enterohepatic circulation and may accelerate PFAS excretion — a concept that has been explored in some case reports of high PFAS-exposed individuals, though not yet in controlled clinical trials.
Implications for Those with Existing Liver or Gallbladder Conditions
For individuals with existing liver disease (NAFLD, hepatitis, cirrhosis) or gallbladder disease (recurrent gallstones, cholecystitis), PFAS water contamination presents additional concern. The hepatotoxic effects of PFAS may compound existing liver vulnerability, and PFAS effects on bile composition may aggravate gallbladder dysfunction.
For these individuals, PFAS exposure reduction through water filtration is particularly motivated. A certified reverse osmosis system, providing 90–99% PFAS removal from drinking water, reduces the daily PFAS load reaching the liver through the portal circulation from gastrointestinal absorption. Discussion of PFAS exposure with a gastroenterologist or hepatologist managing liver or gallbladder conditions is worthwhile for patients in PFAS-contaminated areas.